Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ICLR 
ICON PLC (ICLR)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/29/2025: ICLR (2-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Below Average Performance
These Stocks/ETFs, based on Upturn Advisory, often underperform the market, warranting careful consideration before investing.
Number of Analysts
17 Analysts rated it
Moderately tracked stock, growing coverage, gaining market and investor attention.
1 Year Target Price $216.8
1 Year Target Price $216.8
| 11 | Strong Buy |
| 0 | Buy |
| 6 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 23.19% | Avg. Invested days 49 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  3.0 |
| Profits based on simulation | Last Close 08/29/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 13.84B USD | Price to earnings Ratio 18.31 | 1Y Target Price 216.8 |
Price to earnings Ratio 18.31 | 1Y Target Price 216.8 | ||
Volume (30-day avg) 17 | Beta 1.17 | 52 Weeks Range 125.10 - 323.25 | Updated Date 08/29/2025 |
52 Weeks Range 125.10 - 323.25 | Updated Date 08/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 9.72 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 9.82% | Operating Margin (TTM) 12.83% |
Management Effectiveness
Return on Assets (TTM) 4.35% | Return on Equity (TTM) 8.3% |
Valuation
Trailing PE 18.31 | Forward PE 13.35 | Enterprise Value 16995339812 | Price to Sales(TTM) 1.71 |
Enterprise Value 16995339812 | Price to Sales(TTM) 1.71 | ||
Enterprise Value to Revenue 2.1 | Enterprise Value to EBITDA 12.38 | Shares Outstanding 77772096 | Shares Floating 76795312 |
Shares Outstanding 77772096 | Shares Floating 76795312 | ||
Percent Insiders 0.65 | Percent Institutions 103.27 |
Upturn AI SWOT
ICON PLC
Company Overview
History and Background
ICON PLC was founded in 1990 in Dublin, Ireland. It has grown from a small research organization to a global provider of outsourced clinical development services to the pharmaceutical, biotechnology, and medical device industries.
Core Business Areas
- Clinical Development: Full-service clinical trial management, from protocol design to clinical study report.
- Laboratory Services: Central laboratory testing and biomarker services to support clinical trials.
- Commercialization and Outcomes: Services to support the commercialization of new therapies and demonstrate their value.
- Strategic Consulting: Providing expert advice and strategies to optimize clinical development programs.
Leadership and Structure
ICON is led by CEO Steve Cutler. The organizational structure is divided into functional teams aligned with its core business areas, with a regional presence across North America, Europe, and Asia-Pacific.
Top Products and Market Share
Key Offerings
- Clinical Trial Management: Comprehensive management of clinical trials across all phases. ICON holds approximately 5% market share in the global CRO market. Competitors: IQVIA, Labcorp, PPD (Thermo Fisher Scientific).
- Central Laboratory Services: Provision of laboratory services, including sample management, testing, and data management. ICON's market share within lab services is about 3-4%. Competitors: Labcorp, Quest Diagnostics.
- Real-World Evidence: Generating evidence from real-world data sources to support product development and market access. While difficult to precisely quantify due to its nascent nature, this segment is experiencing significant growth. Competitors: IQVIA, PPD (Thermo Fisher Scientific).
Market Dynamics
Industry Overview
The CRO (Contract Research Organization) industry is growing rapidly due to increased R&D spending by pharmaceutical companies, a focus on outsourcing, and the increasing complexity of clinical trials.
Positioning
ICON PLC is a leading mid-sized CRO known for its expertise in complex clinical trials and its focus on client relationships. It competes with larger and smaller CROs.
Total Addressable Market (TAM)
The global CRO market is estimated to be around $80 billion. ICON PLC is positioned to capture a larger share through strategic acquisitions and organic growth.
Upturn SWOT Analysis
Strengths
- Strong expertise in complex clinical trials
- Global presence
- Long-standing client relationships
- Integrated service offerings
- Focus on innovation and technology
Weaknesses
- Smaller market share compared to larger CROs
- Dependence on key client relationships
- Integration risks associated with acquisitions
- High employee turnover
Opportunities
- Growing demand for outsourced clinical development services
- Expanding into new geographic markets
- Leveraging technology to improve efficiency and reduce costs
- Acquiring smaller CROs to expand service offerings
- Increasing adoption of real-world evidence solutions
Threats
- Intense competition from larger CROs
- Economic downturn affecting pharmaceutical R&D spending
- Regulatory changes impacting clinical trial processes
- Loss of key client relationships
- Data security and privacy risks
Competitors and Market Share
Key Competitors
- IQVIA (IQV)
- Labcorp (LH)
- Thermo Fisher Scientific (TMO) (PPD is a part of it)
Competitive Landscape
ICON PLC differentiates itself through its expertise in complex clinical trials and its focus on client relationships. However, it faces intense competition from larger CROs like IQVIA.
Major Acquisitions
PRA Health Sciences
- Year: 2021
- Acquisition Price (USD millions): 12000
- Strategic Rationale: Expanded ICON's service offerings and global reach, creating a leading global CRO.
Growth Trajectory and Initiatives
Historical Growth: ICON PLC has historically grown through a combination of organic growth and strategic acquisitions.
Future Projections: Analyst projections data unavailable to an AI at this time. Provide data to complete.
Recent Initiatives: Recent initiatives include expansion into new therapeutic areas, investments in technology, and strategic acquisitions to enhance service offerings.
Summary
ICON PLC is a mid-sized CRO with expertise in complex clinical trials, strategically positioning itself via acquisitions. Strengths lie in its global presence and integrated offerings, yet it faces competition from larger companies. Growth opportunities stem from rising demand and technology integration, while potential threats include economic downturns and regulatory shifts. Recent initiatives include expanding service areas and technological investment.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company filings, industry reports, analyst estimates.
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About ICON PLC
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 1998-05-15 | CEO & Director Dr. Steven A. Cutler MBA, Ph.D. | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 39900 | Website https://www.iconplc.com |
Full time employees 39900 | Website https://www.iconplc.com | ||
ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies. It also provides clinical development services, including all phases of development, peri and post approval, data solutions, and site and patient access services; clinical trial management, consulting, and contract staffing services; and commercial services comprising clinical development strategy, planning and trial design, full study execution, and post-market commercialization. In addition, the company offers laboratory services, including bionanalytical, biomarker, vaccine, good manufacturing practice, and central laboratory services, as well as full-service and functional service partnerships to customers. Further, the company provides adaptive trials, cardiac safety solutions, clinical and scientific operations, consulting and advisory, commercial positioning, decentralized and hybrid clinical trials, early clinical, laboratories, language services, medical imaging, real world intelligence, site and patient, and strategic solutions. It serves pharmaceutical, biotechnology, and medical device industries, as well as government and public health organizations. ICON Public Limited Company was incorporated in 1989 and is headquartered in Dublin, Ireland.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.